Cure for thalassemia major – from allogeneic hematopoietic stem cell transplantation to gene therapy | Haematologica
Replacing the suppressed hormone: toward a better treatment for iron overload in β-thalassemia major? | Haematologica
PDF) Pregnancy outcome in patients with -thalassemia intermedia at two tertiary care centers, in Beirut and Milan | Mohammed Naja - Academia.edu
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsiv
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Haematologica, Volume 107, Issue 7 by Haematologica - Issuu
Untitled
Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness | Haematologica
Untitled
Haematologica, Volume 106, Issue 2 by Haematologica - Issuu
Evidence of protective effects of recombinant ADAMTS13 in a humanized model of sickle cell disease | Haematologica
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective | Haematologica
Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia | Haematologica
Haematologica, Volume 107, Issue 11 by Haematologica - Issuu
Haematologica, Volume 104, Issue 4 by Haematologica - Issuu
Tricuspid-valve regurgitant jet velocity as a risk factor for death in β-thalassemia | Haematologica
Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the Europ
Untitled
Untitled
Haematologica, Volume 106, Issue 9 by Haematologica - Issuu
Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective | Haematologica
PDF) Cure for thalassemia major – From allogeneic hematopoietic stem cell transplantation to gene therapy
Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells: Molecular Therapy - Methods & Clinical Development
Vol. 102 No. 4 (2017): April, 2017 | Haematologica
Sickle cell disease is a global prototype for integrative research and healthcare - Royal - 2021 - Advanced Genetics - Wiley Online Library
Haematologica, Volume 102, issue 12 by Haematologica - Issuu
